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Abstract
Background We report our initial gastric electrical stimulation
experience using the abiliti® system for the treatment of obese
patients followed for 1 year.
Method Between March 2011 and June 2013, 27 obese pa-
tients (BMI 30 to 46 kg/m2) were enrolled in a prospective
open label study and implanted with a gastric stimulator. The
patients were provided with nutritional support, and sensor-
based behavioral feedback.
Results At 12 months, percent excess weight loss
(%EWL) obtained was 49.3±19.2 % with no significant
differences between gender or age sub-groups. The
%EWL data were segmented into two groups according
to BMI 30–40 kg/m2 patients (obesity grade I and II) and
BMI >40 kg/m2, with the results of weight loss being
significantly higher for the lower BMI group (59.1±19.5
vs. 46.7±13.4, respectively, p<0.01). One subject re-
quested to have his device explanted, and the minor
postoperative adverse events were resolved without hos-
pital admission. All patients experienced early satiety
and reduced their intake.
Conclusions After 12 months of follow-up, gastric electrical
stimulation treatment appears to be a safe and effective option
for weight loss in obese subjects. Long-term follow-up and
further studies are warranted.
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Introduction
The prevalence of obesity continues to increase [1], the latest
data from Spain show that 24.4 % of the adult male and
21.4 % of female are obese [2]. Bariatric surgery has proven
effective, but is accompanied with morbidity (e.g., leakage,
infection) and side effects. For these reasons, less invasive
solutions for the obesity treatment are sought, providing sat-
isfactory results. One of them is gastric electrical stimulation
(GES) which produces an early feeling of fullness in order to
reduce food intake.
The abiliti® system (IntraPace Inc) consists of a lead
with two electrodes: a transgastric sensor detecting food
intake and a stimulation electrode placed at the lesser
curvature over the vagus. This lead is connected to a
stimulator that sends electrical impulses when intake is
detected. The system includes a 3D accelerometer record-
ing physical activity, and an intragastric food sensor re-
cording daily intake, providing objective data to the med-
ical team. A telemetry link enables data download for
patient monitoring.
The aim of this prospective open label study was to
evaluate the effectiveness of GES on weight loss in a
patient population unwilling to undergo to more inva-
sive bariatric surgery. The study was approved by the
hospital ethics committee and conducted in accordance
with Good Clinical Practice and consistent with the
Declaration of Helsinki. The patients signed informed
consent prior to their participation and supported the
financial costs of their procedures with no IntraPace
financial support provided for either the patient or
clinician.
The devices were implanted in the Obesity Surgery
Unit of our hospital, during the period between March
2011 and June 2013. We present our experience at
12 months post-surgery.
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Patients and Methods
Twenty-seven adults with a BMI in the class I or II obesity
range (World Health Organization) [3] or class III range
unwilling to undergo a bariatric surgery were proposed the
GES treatment alternative.
Patients were required to be >20 years of age, with no
previous of gastric surgery, and willing to comply with the
follow-up schedule, post-procedure diet, and exercise pro-
gram. Multidisciplinary interviews with the medical and sur-
gical teams, baseline lab measurements including HbA1c, and
completion of the Three Factors Eating Questionnaire (TFEQ)
[4] which characterizes the patient’s eating behavior, were
reviewed prior to the surgical decision. GES efficacy was
evaluated using weight loss, expressed as percent excess
weight loss (%EWL), with expectations set at a minimum of
35 % at 12 months. Exploratory analysis on the effects of
gender or baseline BMI on weight loss outcome was per-
formed. Safety data were collected and analyzed during the
study period.
Device Implant Technique
The implant is performed using standard laparoscopic
technique with the usual preoperative protocol for bariat-
ric surgery. The patient was placed in lithotomy position;
a pneumoperitoneum is created by Veress needle puncture
to an intra-abdominal pressure of 14 mmHg. Three ab-
dominal trocars were placed, at midline supra-umbilical
for optical 5th, in the right upper quadrant, and in the left
subcostal region (anterior axillary line). The anterior wall
of the stomach was explored to identify the ideal site for
the electrodes placement. The food sensor was inserted in
the body-fundus region, about 3 cm from the greater
curvature. The stimulation electrode was sutured approx-
imately 4 cm from the gastroesophageal junction and
1.5 cm from the lesser curvature, over the division
branches of the Latarjet nerve (goose’s foot). The distance
between electrodes was 3–4 cm. Upon inflation of the
stomach, a dilating needle is inserted to create an opening
for the insertion of the sensor probe; the silicon flange is
then secured to the serosa, to prevent the electrode reced-
ing through the gastric conduit in the peritoneal cavity
(Fig. 1).
Fig. 1 The transgastric food sensor is secured to the gastric serosa by
suturing the silicon flange
Fig. 2 Intragastric extension of the food sensor probe
Fig. 3 The stimulation electrode is secured to the serosa over the vagus
nerve branches
Table 1 Baseline demographics (mean±SD (range)), all subject
implanted
Gender Female, n=18 (66.6 %),







Obesity grade I n=4 (14.8 %)
Obesity grade II n=9 (33.3 %)
Obesity grade III n=14 (51.9 %)
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An endoscopic exam confirmed the intragastric position of
the sensor probe and its extension into the gastric lumen (10–
11 mm) (Fig. 2).
The stimulating electrode is placed flush to the stomach
surface over the vagus branches and secured to the serosa. It is
important to verify that the lead length between the sensor and
stimulation electrode is adequate to accommodate the gastric
distension (Fig. 3).
The proximal end of the lead is externalized to the subcu-
taneous pocket created to fit the stimulator. The two lead
probes are inserted and secured in the stimulator ports, and
the excess lead is coiled under the stimulator for protection;
the pocket is then closed with absorbable sutures.
Post-Implant Follow-up
All the patients were discharged 12–24 h after surgery
with liquid or soft diet for 48 h. Their devices were
programmed to deliver a mild stimulation at mealtimes.
One week post-surgery, the patients attend a consultation
for surgical site evaluation and tailoring programmed
stimulation. The patients are seen monthly for the first
3 months post-surgery then, every 2 to 12 months. At
each visit, nutritional plan and physical activity
guidelines were reviewed and stimulation parameters
were adjusted if needed.
Statistical Analyses
Baseline subject characteristics were summarized using mean
±SD for continuous variables and n and percent for categor-
ical variables. Excess weight loss (EWL) was calculated using
the measured weight minus ideal weight, determined accord-
ing to the WHO recommended healthy BMI of 25. Sub-group
analysis was done using the Student t test for statistical sig-
nificance to determine the association of BMI, gender, and age
with %EWL at 1 year.
Results
Twenty seven obese subjects with no associated comorbidities
underwent the device implant. One subject requested her
device explanted after 2 months and is not included in this
analysis. Nine men and seventeen women completed the 12-
month follow-up. The baseline characteristics are reported in
Table 1.
Efficacy
At 12 months, the %EWL, percent weight loss (%WL) and
weight loss for all the subjects were 49.3±19.2 %, 17.0±
5.0 %, and 19.1±6.5 kg (mean±SD), respectively. No signif-
icant difference in %EWL was found between gender (9 M,
17 F) 49.4±15.8 % vs. 49.2±21.2 %, respectively, or age
<45 years (n=14) vs. ≥45 years (n=12), 50.5±22.5 % vs.
48.2±15.9 % (mean±SD), respectively (Fig. 4).
A sub-analysis according to the baseline BMI was per-
formed—BMI 30–40 (n=13) and BMI >40 (n=13). At
12 months, the analysis show a significant difference between
lower and higher BMI groups in%EWL (%EWL 59.1±19.5 vs.
46.7±13.4, respectively, p<0.01). The%EWL calculated at 3, 6,
9, and 12 months are presented in Fig. 5 and Table 2. In both
Fig. 4 %EWL difference between gender males (n=9) and females (n=
17), or age group <44.5 years old (n=14) and >44.5 years old (n=12)
Fig. 5 %Excess weight loss at 3,
6, 9, and 12 months for subjects
with BMI 30–40 m2/kg (n=13)
blue line and with BMI >40 m2/
kg (n=13) red line
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groups, our minimal goal of 35 % was exceeded; 22 subjects
(84.6 %) obtained a %EWL>35 % at 12 months (Fig. 6).
Safety
The average duration of surgery was 50.1±11.0 min
(range 37–73) without any intra-operative complication.
There was no death; all patients were discharged 12–24 h
post-surgery. Two subjects presented a mild fever in
immediate post-surgery with no clinical or surgical diag-
nosis evident. The fever receded with oral antibiotic and
did not delay the patient hospital discharge. One patient
requested her device to be explanted after 2 months
stating that she did not achieve her desired weight loss.
The device was explanted under a laparoscopic
procedure.
Three patients presented with mild stomach cramping dur-
ing the stimulation period, these symptoms disappeared with
stimulation reprogramming. There was no other therapy side
effects reported (e.g., nausea, vomiting) during the study
period.
Discussion
GES with abiliti produced an early sensation of fullness and
satiety as reported by the patients, helping to reduce their food
intakes. The surgical procedure is minimally invasive with
minor complications in comparison with other bariatric
surgeries.
The GES Transcend® system showed an efficacy ranging
from 21 to 23 % EWL at 12 months [5–9], the Tantalus-
Diamond® (Metacure) designed for contractility modulatory
therapy improved glycaemic control and caused a modest
weight loss in patients with Type 2 diabetes 5.4±1.6 %WL
at 12 months [10] , and most recent ly, VBLOC
(EnteroMedics), a system designed for a non-selective block
of vagus activity, obtained 25 % EWL at 12 months [11]. The
Table 2 Mean percent excess






BMI 30–40 Kg/m2 (n=13) BMI >40 Kg/m2 (n=13)
3 21.8±10.5 (7–51) 27.1±11.5 (11–51) 19.5±6.1 (7–26)
6 35.3±14.7 (14–70) 42.8±16.0 (20–70) 33.0±8.7 (14–44)
9 44.2±17.3 (13–82) 53.2±17.5 (37–81) 41.5±11.6 (13–61)
12 49.3±19.2 (10–90) 59.1±19.5 (34–90) 46.7±13.4 (10–68)
Fig. 6 Percentage of patients that
achieved different %EWL
milestones at 12 months. Blue
column total population (n=26),
red column patients with BMI
30–40 m2/kg (n=13), green
column patients with BMI
>40 m2/kg (n=13). Greater than
80 % of the population met the
study goal of >35 % EWL
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location and parameters of the abiliti® are similar to the
Transcend, and studies have shown that this type of stimula-
tion food intake reduction is probably driven by direct and
indirect activation of afferent neural pathways in the vagus
nerve that produce a satiety response [12–14]. Improved effi-
cacy of the abiliti may be related to more selective activation
of vagal afferents through patient-tailored stimulation. Also,
the “sensor intake dependant” stimulation versus continuous
stimulation reduces significantly the neuromuscular adapta-
tion phenomenon [15] probably responsible for loss of effica-
cy. Finally, providing stimulation above a subject’s symptom-
atic threshold supports conscious modification of eating
behavior.
In addition to food intake, physical activity is detected by
the device 24 h a day; these data may be discussed with the
patient, providing behavioral feedback, helping to correct
efficiently the patient’s lifestyle. Combining the effect of
gastric stimulation with behavioral management likely leads
to more significant weight loss results.
The minimum target of 35 % EWL was chosen based on
the weight loss efficacy range observed with gastric banding
[16]. The range of WL achieved in our population was wide
(10 to 90 % EWL with a mean of 49.3 %); however, only two
patients achieved less than 30 % EWL, and both had a BMI
>40 at baseline. We hypothesize that initial patient’s screening
based on physiological or psychological characteristics and
eating behavior profile would lead to better results. The aver-
age ofWL 19.1±6.5 kg or 17.0±5.0 % achieved exceeded the
weight loss shown to result in meaningful reduction in mor-
tality and comorbidities [17–19]; the authors conclude that
moderate weight loss of 10 % results in a 25 % reduction in
overall mortality, 40 % reduction in diabetes-related deaths,
and 50 % reduction in obesity-related malignancy and also
reduced the incidence of hypertension, hypercholesterolemia,
and type 2 diabetes.
Conclusions
Gastric electrical vagal neuro-modulation is a valuable
option to treat obesity. The results obtained are similar
to restrictive procedures. GES creates early sensation of
fullness and food intake reduction to obtain significant
weight loss. The information tracked by the food sensor
and the accelerometer help physicians in obesity manage-
ment programs. This therapy facilitates and enhances the
behavior monitoring programs developed in our hospital.
Studying more patients will increase our expertise in
gastric neurostimulation and help define the most respon-
sive population. Possible mechanisms of action of this
therapy remain to be defined. These results need to be
confirmed with additional clinical studies.
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